In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauren Nardella

Lauren Nardella covers health care business topics, including contributions for more than a decade to HBW Insight (and previously the Rose Sheet) for more than a decade, where’s she has covered the regulation, business, science and policy of the cosmetics and personal-care products industries. She enjoys tackling complex issues and turning them into stories that help readers stay abreast of current topics. Nardella was previously a business reporter for various daily newspapers. She lives in Northern Virginia.

Latest From Lauren Nardella

Federal Ban On PFAs In Cosmetics Could Ensure National Uniformity; It Also Could Drive Litigation

While studies are limited regarding the human health effects of PFAS in cosmetic products, efforts to prohibit their use continue gaining steam at the state and federal levels, which could lead to increased litigation.

Legislation Cosmetic Ingredients

California DTSC To Focus On Nail Product Regs With Greatest Impact – Safer Consumer Product Leaders

Following the release of a comprehensive survey of chemicals of concern in nail products on the California market, the state’s Department of Toxic Substances Control has a better idea of nail product ingredient use, which could help inform future rulemaking.

Regulation US States

‘We Can’t Go Back In Time’: CIR Panel Grapples With Prostaglandins Review Without Animal Test Data

In its safety assessment of two prostaglandin analogues, the Expert Panel for Cosmetic Ingredient Safety determined that certain read-across data from potentially related ingredients were not enough to extrapolate and apply to a prostaglandin review. This and more from the panel's 4-5 December meeting.

Cosmetic Ingredients Safety

The Replacements: Cosmetic Ingredient Suppliers At Ready With Microplastic Alternatives As EU Ban Unfolds

HBW Insight reached out to suppliers of microplastic alternatives for cosmetics use to discuss their offerings and preparedness for demand surges under phased REACH prohibitions.

Regulation Cosmetic Ingredients

Akili Awaits FDA Feedback On Data Needs For OTC Marketing Of ADHD Digital Therapeutic

The DTx company’s revenue grew some 500% to $702,000 in the fiscal 2023 third quarter, reflecting its direct-to-consumer launch of EndeavorOTC to adult ADHD patients in June under a US FDA enforcement policy established for digital health devices during the COVID-19 public health emergency. That policy has since sunset, and Akili has submitted a 510(k) application to the agency for review.

Digital Health FDA

Akili Awaits FDA Feedback On Data Needs For OTC Marketing Of ADHD Digital Therapeutic

The DTx company’s revenue grew some 500% to $702,000 in the fiscal 2023 third quarter, reflecting its direct-to-consumer launch of EndeavorOTC to adult ADHD patients in June under a US FDA enforcement policy established for digital health devices during the COVID-19 public health emergency. That policy has since sunset, and Akili has submitted a 510(k) application to the agency for review.

Digital Health FDA
See All
UsernamePublicRestriction

Register